PeproMene Bio Appoints Steven T. Rosen, MD, to the Scientific Advisory Board
Irvine, CA, June 22, 2018 – PeproMene Bio, Inc., a development stage biotechnology company focused on BAFF-R target CAR-T cell to develop novel cancer and immuno-oncology therapies, today announced the appointment of Steven T. Rosen as its Scientific Advisor.
Bryan Hong Woo Kim, Chief Executive Officer at PeproMene Bio, said, “We are pleased to welcome Dr. Rosen to the Company, as we are building our advisory board for the incoming clinical trials.”
Dr. Rosen is provost and chief scientific officer for City of Hope. He is currently director of the comprehensive cancer center, Beckman Research Institute of City of Hope and the Irell & Manella Graduate School of Biological Sciences, holds the Irell & Manella Cancer Center Director's Distinguished Chair and the Morgan & Helen Chu Director’s Chair of the Beckman Research Institute.
About PeproMene Bio
PeproMene Bio, Inc. is a virtual, privately funded biotech company located Irvine, CA. We are developing novel immune-oncology therapies such as BAFF-R CAR-T therapy based on the novel antibodies. The BAFF-R CAR-T therapy program which was discovered and developed from Dr. Larry Kwak’s lab at MD Anderson and City of Hope was successfully licensed in from City of Hope, Duarte CA, in April 2017. Currently the further development is on going at City of Hope for its IND enabling study. We will continue to license-in and explore more of novel immuno-oncology programs via our network. For more information about the Company, please visit www.pepromenebio.com.
Steve Lee: 714-599-8077, email@example.com